India's largest drugmaker Sun Pharma is confident that its specialty sales business will continue its growth momentum and ...

In a warning letter, the FDA has highlighted a series of lapses at Sun Pharma’s Gujarat plant, which has been put on an import alert list by the US drug regulator. In the letter dated December ...

For the US import alert to be lifted, Sun Pharma must conduct an independent, retrospective assessment of its cleaning effectiveness and cross-contamination hazards. The company was given 15 working ...

The company intends to increase its specialty drug portfolio in its core areas of dermatology and ophthalmology. This comes ...

Sun Pharmaceutical Industries posted a 5.2 percent year-on-year (YoY) rise in net profit for the third quarter of Financial ...

Sun Pharmaceutical Industries, a leading Indian pharma giant with revenues of over Rs. 38,400 crore plus, has posted consolidated revenue growth of 14 per cent during the third quarter ended December ...

Shares of Sun Pharma rose today after falling for five consecutive sessions as the healthcare firm said the company would not revise its revenue guidance downwards for the current financial year ...

India's largest drugmaker Sun Pharmaceuticals Ltd. is likely to report a healthy quarter despite the weakness from its ...

Sun Pharmaceutical Industries Ltd , India's largest drugmaker by revenue, reported a better-than-expected 5.2% rise in ...

The Food and Drug Administration has filed a lawsuit accusing a Boca Raton pharmaceutical company ... from suppliers on the FDA’s Import Alerts list, which gives the agency authority to detain ...

Sun Pharma's immediate focus would be to follow Concert's plan to submit a marketing application to the FDA in 1H of 2023 ... Don't miss real-time alerts on your stocks - join Benzinga Pro ...